Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eosinophilic Esophagitis Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis

NCT03822325
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Pilot)

NCT03812575
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 28, 2026, 8:28 PM EDT
Terminated Phase 2 Interventional Results available

Bethanechol for Eosinophilic Esophagitis

NCT02058537
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Bethanechol
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Specimen Collection, Questionnaires
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 8:28 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Esophageal Absorption in EoE

NCT02314455
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
D-xylose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eating With Eosinophilic Esophagitis (EoE)

NCT03581838
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Observed eating session
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 28, 2026, 8:28 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04620811
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions
lirentelimab
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Not applicable Interventional

CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

NCT03342391
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Transnasal esophagoscopy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 22 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 28, 2026, 8:28 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of the Esophagus Using a SECM Capsule

NCT03546660
View directory record Official record
Conditions
Eosinophilic Esophagitis, Barrett Esophagus
Interventions
SECM capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Image the Esophagus Using the OFDI Capsule

NCT02204150
View directory record Official record
Conditions
Barrett's Esophagus, Eosinophilic Esophagitis
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

NCT04856891
View directory record Official record
Conditions
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

NCT05247866
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose, Dupilumab
Dietary Supplement · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia

NCT00256529
View directory record Official record
Conditions
Esophagitis
Interventions
EGD with biopsies
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

NCT02775045
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Observation Period
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 1 Interventional

Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients

NCT01641913
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Absorbable sugars
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 28, 2026, 8:28 PM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 8:28 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Esophageal String Test in Eosinophilic Esophagitis

NCT02008903
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis

NCT01170234
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NIOX MINO® Airway Inflammation Monitor
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
7 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 28, 2026, 8:28 PM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 28, 2026, 8:28 PM EDT
Completed No phase listed Observational

Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

NCT01929824
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Nitric Oxide testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 28, 2026, 8:28 PM EDT